Immunitas Therapeutics, Inc. is a biotechnology company focused on developing therapies for chronic inflammatory and autoimmune diseases. The company’s pipeline includes a preclinical antibody program that selectively targets pathogenic cells at sites of inflammation, aiming for deeper and more durable disease control in patients who do not respond adequately to existing treatments.
Official website: immunitastx.com
